Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Acquisitions & Divestments: 2014-2024

Historic Change in Acquisitions & Divestments for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Dec 2024 value amounting to $337.3 million.

  • Syndax Pharmaceuticals' Change in Acquisitions & Divestments rose 2.79% to $103.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $448.6 million, marking a year-over-year increase of 30.82%. This contributed to the annual value of $337.3 million for FY2024, which is 28.58% down from last year.
  • Syndax Pharmaceuticals' Change in Acquisitions & Divestments amounted to $337.3 million in FY2024, which was down 28.58% from $472.2 million recorded in FY2023.
  • Syndax Pharmaceuticals' 5-year Change in Acquisitions & Divestments high stood at $472.2 million for FY2023, and its period low was $136.4 million during FY2020.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $337.3 million (2024), whereas its average is $372.8 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first spiked by 86.19% in 2021, then decreased by 28.58% in 2024.
  • Over the past 5 years, Syndax Pharmaceuticals' Change in Acquisitions & Divestments (Yearly) stood at $136.4 million in 2020, then soared by 86.19% to $254.0 million in 2021, then grew by 21.64% to $308.9 million in 2022, then skyrocketed by 52.85% to $472.2 million in 2023, then fell by 28.58% to $337.3 million in 2024.